公开(公告)号：US20150118234A1

公开(公告)日：2015-04-30

申请号：US14584664

申请日：2014-12-29

Applicant: Tasuku HONJO ,  ONO PHARMACEUTICAL CO., LTD.

Inventor： Tasuku HONJO ,  Shiro SHIBAYAMA ,  Kazuhiko TAKEDA ,  Masayoshi MATSUO ,  Takao YOSHIDA ,  Masakazu MIYAMOTO

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/73

Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Abstract translation: 本发明涉及对人PD-1特异性的物质，其包含识别人PD-1的部分，识别人PD-1表达细胞的细胞膜中的膜蛋白的部分和接头。 由于对人PD-1特异性的物质可以选择性地识别人PD-1和人PD-1表达细胞的细胞膜上的膜蛋白，并且可以传递人PD-1的抑制信号，因此它可用于治疗和/或 预防免疫病引起的疾病。

公开(公告)号：US20130085275A1

公开(公告)日：2013-04-04

申请号：US13682784

申请日：2012-11-21

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Yoshikazu TAKAOKA ,  Shiro SHIBAYAMA ,  Rena NISHIZAWA

IPC: C07D413/12 ,  C07D401/06 ,  C07D401/14 ,  C07D401/12 ,  C07D211/58

CPC classification number: C07D413/12 ,  A61K31/00 ,  C07D211/58 ,  C07D231/12 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D409/14

Abstract: A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

Abstract translation: 由式（I）表示的化合物，其盐，其N-氧化物，其溶剂合物或其前药：（其中各符号如说明书中所定义）。式（I）表示的化合物具有拮抗作用 因此它们可用于预防和/或治疗CCR5相关疾病，例如各种炎性疾病（哮喘，肾炎，肾病，肝炎，关节炎，类风湿关节炎，鼻炎，结膜炎，炎性肠病如溃疡性结肠炎） 等等），免疫疾病（自身免疫性疾病，器官移植排斥反应（实体器官移植排斥反应，胰岛细胞移植对糖尿病的治疗排斥反应，移植物抗宿主病等），免疫抑制，牛皮癣， 多发性硬化症等），感染性疾病（人类免疫缺陷病毒感染，获得性免疫缺陷综合征，RSV感染等），过敏性疾病（特应性皮炎，荨麻疹，过敏性 急性呼吸窘迫综合征，伴随细菌感染的休克，糖尿病，癌症转移等），心血管疾病（动脉硬化，缺血再灌注损伤等）。